0RN4 Stock Chart & Stats
kr1.60
>-kr0.01(-0.37%)
At close: 4:00 PM EDT
kr1.60
>-kr0.01(-0.37%)
Day’s Range― - ―
52-Week Rangekr1.27 - kr6.14
Previous CloseN/A
Volume928.00
Average Volume (3M)21.14K
Market Cap
kr629.66M
Enterprise Valuekr595.78
Total Cash (Recent Filing)kr205.15M
Total Debt (Recent Filing)kr130.80M
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding381,148,130
10 Day Avg. Volume23,007
30 Day Avg. Volume21,142
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)-18.53
Price to Sales (P/S)15.35
P/FCF Ratio-4.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)kr141.30M
Bulls Say, Bears Say
Bulls Say
Improving RevenueRevenue growth indicates improving commercial traction for Oncopeptides’ oncology portfolio. Sustained expansion would provide a larger base over which the company can spread its development, regulatory, and commercial costs.
Exceptional Gross MarginThe exceptionally high gross margin is consistent with the economics of a differentiated pharmaceutical product. If maintained as sales scale, it could support meaningful operating leverage once spending and infrastructure become better aligned with revenue.
Narrowing LossesLosses remain substantial, but the improvement in net margin suggests some progress toward a more sustainable earnings profile. Continued reduction in losses would lower the company’s dependence on external funding over time.
Bears Say
Severe Cash BurnPersistent negative operating and free cash flow shows that current operations do not fund the business. Continued cash consumption increases refinancing or dilution risk and may constrain investment in commercialization and pipeline development.
Elevated LeverageHigh leverage is challenging for a company that remains loss-making and cash-flow negative. Debt obligations reduce financial flexibility, while the need for continued funding access could weaken negotiating power with lenders or investors.
Large Operating LossesThe cost base remains far larger than the company’s current revenue, leaving Oncopeptides well short of break-even. Unless revenue scales materially or expenses fall, profitability and self-sustaining operations remain distant.
Oncopeptides AB News
0RN4 FAQ
What was Oncopeptides AB’s price range in the past 12 months?
Oncopeptides AB lowest share price was kr1.27 and its highest was kr6.14 in the past 12 months.
What is Oncopeptides AB’s market cap?
Oncopeptides AB’s market cap is kr629.66M.
When is Oncopeptides AB’s upcoming earnings report date?
Oncopeptides AB’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.
How were Oncopeptides AB’s earnings last quarter?
Oncopeptides AB released its earnings results on Aug 27, 2026. The company reported -kr0.144 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Oncopeptides AB overvalued?
According to Wall Street analysts Oncopeptides AB’s price is currently Overvalued.
Does Oncopeptides AB pay dividends?
Oncopeptides AB does not currently pay dividends.
What is Oncopeptides AB’s EPS estimate?
Oncopeptides AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncopeptides AB have?
Oncopeptides AB has 381,148,130 shares outstanding.
What happened to Oncopeptides AB’s price movement after its last earnings report?
Oncopeptides AB reported an EPS of -kr0.144 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 19.321%.
Which hedge fund is a major shareholder of Oncopeptides AB?
Currently, no hedge funds are holding shares in GB:0RN4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncopeptides AB
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
Technical Analysis
Alligator Bioscience AB
―
BioInvent International AB
―
Immunicum AB
―
Cantargia AB
―
Sprint Bioscience AB
―